📇 Rhumatologue ·
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
18 articles scientifiques publiés — formation continue solide
Référence presse grand public
Cité 3 fois dans les médias — pédagogie reconnue
✨ Génération du profil synthétique IA en cours…
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 La Tribune · 26/02/2020
<a href="https://news.google.com/rss/articles/CBMiigJBVV95cUxNelY1dVdHMkZoRWZ5X2g5TkVEVVR0S3VUVXRJS1RQNEtiWXdsUldjVU00Vm1KN3U0aWZDc1dZalF5eDdTdWxSQldZcXVMWi1UX002NzFaTDZrV3B0QlZCYnBOMUZRdGhuekQ1cVFyd3lhTEdNV1FqeGgtYTMwRWZMa1ZkSlNhRUFVSFlpSWZzdHFkSFEzTkFMYmhUX3dFNmFsNW5MdmloSVN0QTdkQ1JFUHBlTHRGejFlVj
📰 Le Figaro Santé · 18/03/2014
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQb3NIVEdqOHZtV25tVm9TeUhfa1hldGxFZ3RDcW5ZS3VBaGlMSzJXb2l3ZTJKcjBfUTIxdGM0bm80cUtPNVlKZWlJZlBTX0NNRGZzU2Y0Q3RJTjlVUkx5eDN0d25KTHNrWFZfY0pNX0RnUDB5NU5CV09iTWplSGZVSm56ZWZDSjMzVmJBMl8tZVFOMkZ3VEd3VHJRTWRpQThuN3c?oc=5" target="_blank">Guide su
📰 Le Monde.fr · 22/07/2013
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxNdFgzVmdITUh0VkdoSGw5LVVHMU5vRWdZbF9PcHZEM2pQbk9vYnhUdDZVRzgtelk2cGRCdkVNRGxJT3lNR3NNSlgta1djRGVnNGZqdzBleWowZTIxd1M5OFZEcWN6bnUzeUg5YjltOGprdTBPMVF5WDJnMUs5VVJVSkR0dWY4aUdpWmdILXktNGQ5eGg5WkxPMWc0amQxamNfN1o1Q1kxcHhQRXduR2hQMV9jUE1pOW91X0
Ophthalmology · 2004
Investigative ophthalmology & visual science · 2004
British journal of clinical pharmacology · 2009
WHAT IT IS ALREADY KNOW ABOUT THIS SUBJECT • Amiodarone is a highly effective antiarrhythmic drug, but is limited in practice by its adverse effects, which are frequent on long‐term administration and can be severe.• Amiodarone is very lipophilic and attains high concentrations in many tissues.• Excessive accumulation in tissues is suspected as a possible cause of some of its adverse events, but sampling affected tissues (e.g. lung, thyroid, heart) in vivo is difficult.• Subcutaneous adipose tissue is more easily obtained, and studying concentrations of amiodarone and N‐desethyl‐amiodarone there could help to understand how amiodarone distributes and accumulates in tissues in general. WHAT THIS STUDY ADDS • No evidence of excessive or unexpected accumulation of amiodarone in fat tissue, with respect to dose, was found in patients treated for >3 months.• Concentrations in plasma and subcutaneous fat tissue were better related to maintenance daily dose than to cumulated dose or treatment duration.• Clinically relevant adverse effects of amiodarone, for the most part hypothyroidism, were significantly associated with longer duration of treatment and larger cumulated doses.• In contrast, adverse events were not correlated with higher amiodarone or N‐desethyl‐amiodarone concentrations, whether in plasma or in adipose subcutaneous tissue.• The measurement of these concentrations does not seem useful in predicting the risk of adverse effects.AIMS To determine if amiodarone, highly lipophilic, accumulates in excess with respect to dose in fat tissue during long‐term administration, and study if plasma and fat tissue concentrations are correlated with adverse effects.METHODS Trough concentrations of amiodarone and N‐desethyl‐amiodarone were measured simultaneously in plasma and fat tissue, in 30 consecutive patients treated with amiodarone for 3 months to 12 years. Subcutaneous adipose tissue was obtained by needle aspiration from lumbar and abdominal areas. Concentrations were measured by liquid chromatography–tandem mass spectrometry.RESULTS Plasma levels of amiodarone and N‐desethyl‐amiodarone were significantly correlated with daily maintenance doses (R= 0.52, P= 0.003). Amiodarone concentrations in fat tissue were four to 226 times (mean 55) higher than in plasma, and well correlated with plasma levels (R= 0.68, P < 0.001). Concentrations of amiodarone and N‐desethyl‐amiodarone in adipose tissue did not significantly increase with higher total cumulated doses or longer treatment duration. Nine of 12 patients who had received amiodarone for ≥2 years developed clinically important adverse effects, predominantly hypothyroidism (n= 6), compared with two of 18 patients treated for less time (relative risk 6.75; 95% confidence interval 1.8, 26). The incidence of those adverse effects was not significantly associated with amiodarone concentrations, whether in plasma or in adipose tissue.CONCLUSIONS We found no evidence of excessive or unexpected accumulation of amiodarone in fat tissue on long‐term administration. Late amiodarone adverse effects, particularly hypothyroidism, are associated with longer exposure times, but do not seem to be explained by higher concentrations in plasma or in fat tissue.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
British journal of clinical pharmacology · 2009 · Journal Article
Lafuente-Lafuente C, Alvarez JC, Leenhardt A, Mouly S, et al.
Current treatment options in cardiovascular medicine · 2005 · Journal Article
Mahé I, Caulin C, Bergmann JF
The journals of gerontology. Series A, Biological sciences and medical sciences · 2004 · Journal Article
Mahé I, Grenard AS, Joyeux N, Caulin C, et al.
Investigative ophthalmology & visual science · 2004 · Journal Article
Audren F, Tod M, Massin P, Benosman R, et al.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis · 2004 · Journal Article
Mahé I, Drouet L, Simoneau G, Minh-Muzeaux S, et al.
Ophthalmology · 2004 · Clinical Trial
Massin P, Audren F, Haouchine B, Erginay A, et al.
Antimicrobial agents and chemotherapy · 2004 · Clinical Trial
Trout H, Mentré F, Panhard X, Kodjo A, et al.
Scandinavian journal of infectious diseases · 2004 · Case Reports
Sellier P, Clevenbergh P, Mazeron MC, Cazals-Hatem D, et al.
Therapie · 2003 · Journal Article
Mahé I, Grenard AS, Caulin C, Bergmann JF
European journal of heart failure · 2003 · Comparative Study
Meune C, Mahé I, Mourad JJ, Cohen-Solal A, et al.
American journal of cardiovascular drugs : drugs, devices, and other interventions · 2003 · Journal Article
Mahé I, Chassany O, Grenard AS, Caulin C, et al.
La Revue du praticien · 2002 · English Abstract
Caulin C
Drugs & aging · 2003 · Journal Article
Mahé I, Leizorovicz A, Caulin C, Bergmann JF
Pathophysiology of haemostasis and thrombosis · 2002 · Journal Article
Mahé I, Drouet L, Chassany O, Grenard AS, et al.
Haematologica · 2006 · Comparative Study
Mahé I, Bertrand N, Drouet L, Bal Dit Sollier C, et al.
La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris · 1977 · Case Reports
Kahn MF, Manicacci M, Segresta JM, Caulin C, et al.
Therapie · 2003 · Journal Article
Vassal G, Méry-Mignard D, Caulin C
Drug safety · 2004 · Journal Article
Mahé I, Caulin C, Bergmann JF
Drug safety · 2004 · Journal Article
Mahé I, Caulin C, Bergmann JF
✨ Profil synthétique
IA · 21/05/2026Le Dr Charles Caulin est un rhumatologue qui a publié des travaux sur diverses pathologies et sujets médicaux. Ses publications sur PubMed couvrent des domaines tels que la gériatrie, les essais cliniques et la pharmacovigilance. Il a également publié sur des sujets spécifiques comme le lupus et la pédiatrie.
Expertises présumées
Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.